| pubmed-article:12855261 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C0332157 | lld:lifeskim |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:12855261 | lifeskim:mentions | umls-concept:C0205373 | lld:lifeskim |
| pubmed-article:12855261 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:12855261 | pubmed:dateCreated | 2003-7-11 | lld:pubmed |
| pubmed-article:12855261 | pubmed:abstractText | A number of recent clinical trials testing the combination of 5-fluorouracil (5-FU) and gemcitabine in patients with advanced pancreatic adenocarcinoma have shown a significant clinical response rate, but also significant toxicity. As the two antimetabolites may interact at several biochemical levels along their pathways of activation, we investigated whether gemcitabine (GEM) affects 5-FU pharmacokinetics in cancer patients. Thus, we compared 5-FU pharmacokinetics in two groups of patients with various cancers who received the same schedule of 5-FU and folinic acid (FUFA), with or without GEM. There was a significant increase in systemic (5-FU) exposure and toxicity in the FUFA plus GEM group. Our finding may be useful in designing future studies of the combination in order to reduce the occurrence of side-effects and to maximise the antitumour activity. | lld:pubmed |
| pubmed-article:12855261 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12855261 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855261 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12855261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12855261 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12855261 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12855261 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:PintoEE | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:FranciniGG | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:GiorgiGG | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:CerretaniDD | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:SabatinoMM | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:CorrealePP | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:RovielloFF | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:PetrioliRR | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:MarsiliSS | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:PozzessereDD | lld:pubmed |
| pubmed-article:12855261 | pubmed:author | pubmed-author:MessineseSS | lld:pubmed |
| pubmed-article:12855261 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12855261 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:12855261 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12855261 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12855261 | pubmed:pagination | 1547-51 | lld:pubmed |
| pubmed-article:12855261 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:meshHeading | pubmed-meshheading:12855261... | lld:pubmed |
| pubmed-article:12855261 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12855261 | pubmed:articleTitle | Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. | lld:pubmed |
| pubmed-article:12855261 | pubmed:affiliation | Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy. | lld:pubmed |
| pubmed-article:12855261 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12855261 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12855261 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12855261 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:12855261 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:12855261 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855261 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855261 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12855261 | lld:pubmed |
